119 related articles for article (PubMed ID: 2184504)
1. Susceptibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies.
Galgiani JN
Rev Infect Dis; 1990; 12 Suppl 3():S272-5. PubMed ID: 2184504
[TBL] [Abstract][Full Text] [Related]
2. [Multicenter study of fungemia due to yeasts in Argentina].
Rodero L; Davel G; Soria M; Vivot W; Córdoba S; Canteros CE; Saporiti A;
Rev Argent Microbiol; 2005; 37(4):189-95. PubMed ID: 16502638
[TBL] [Abstract][Full Text] [Related]
3. Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response?
Graybill JR; Najvar LK; Holmberg JD; Correa A; Luther MF
Antimicrob Agents Chemother; 1995 Oct; 39(10):2197-200. PubMed ID: 8619566
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts.
Mondello F; De Bernardis F; Girolamo A; Salvatore G; Cassone A
J Antimicrob Chemother; 2003 May; 51(5):1223-9. PubMed ID: 12668571
[TBL] [Abstract][Full Text] [Related]
5. Berberine Antifungal Activity in Fluconazole-Resistant Pathogenic Yeasts: Action Mechanism Evaluated by Flow Cytometry and Biofilm Growth Inhibition in Candida spp.
da Silva AR; de Andrade Neto JB; da Silva CR; Campos Rde S; Costa Silva RA; Freitas DD; do Nascimento FB; de Andrade LN; Sampaio LS; Grangeiro TB; Magalhães HI; Cavalcanti BC; de Moraes MO; Nobre Júnior HV
Antimicrob Agents Chemother; 2016 Jun; 60(6):3551-7. PubMed ID: 27021328
[TBL] [Abstract][Full Text] [Related]
6. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
7. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients.
Troillet N; Durussel C; Bille J; Glauser MP; Chave JP
Eur J Clin Microbiol Infect Dis; 1993 Dec; 12(12):911-5. PubMed ID: 8187785
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp.
Del Poeta M; Bixel AS; Barchiesi F; Tidwell RR; Boykin D; Scalise G; Perfect JR
J Antimicrob Chemother; 1999 Aug; 44(2):223-8. PubMed ID: 10473229
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Fluconazole Global Susceptibility Study Group.
Bille J; Glauser MP
Eur J Clin Microbiol Infect Dis; 1997 Dec; 16(12):924-8. PubMed ID: 9495675
[TBL] [Abstract][Full Text] [Related]
10. The antiproliferative peptide Ctn[15-34] is active against multidrug-resistant yeasts Candida albicans and Cryptococcus neoformans.
de Aguiar FLL; Cavalcante CSDP; Dos Santos Fontenelle RO; Falcão CB; Andreu D; Rádis-Baptista G
J Appl Microbiol; 2020 Feb; 128(2):414-425. PubMed ID: 31626724
[TBL] [Abstract][Full Text] [Related]
11. [Antimycotic activity in vitro and in vivo of 5-fluorocytosine on pathogenic strains of Candida albicans and Cryptococcus neoformans].
Costa AL; Valenti A; Costa G; Calogero F
G Batteriol Virol Immunol; 1976; 69(7-12):244-9. PubMed ID: 800772
[TBL] [Abstract][Full Text] [Related]
12. Effect of culture media on in vitro susceptibility testing of fluconazole against some yeasts.
Sekhon AS; Garg AK; Hamir Z
Mycoses; 1991; 34(7-8):319-22. PubMed ID: 1803235
[TBL] [Abstract][Full Text] [Related]
13. Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice.
Kamai Y; Kakuta M; Shibayama T; Fukuoka T; Kuwahara S
Antimicrob Agents Chemother; 2005 Jan; 49(1):52-6. PubMed ID: 15616275
[TBL] [Abstract][Full Text] [Related]
14. Activity of fluconazole against Candida albicans isolates from HIV+ patients in a digestive candidosis turkey model.
Reynes J; Mallie M; Ravisse P; Bastide JM
J Med Vet Mycol; 1992; 30(5):363-7. PubMed ID: 1469537
[TBL] [Abstract][Full Text] [Related]
15. ZD0870 treatment of murine candidiasis caused by fluconazole resistant isolates of Candida albicans.
Najvar LK; Correa A; James P; Luther MF; Graybill JR
J Antimicrob Chemother; 1996 Oct; 38(4):671-7. PubMed ID: 8937961
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.
Morace G; Manzara S; Dettori G
Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239
[TBL] [Abstract][Full Text] [Related]
17. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi.
Mansfield BE; Oltean HN; Oliver BG; Hoot SJ; Leyde SE; Hedstrom L; White TC
PLoS Pathog; 2010 Sep; 6(9):e1001126. PubMed ID: 20941354
[TBL] [Abstract][Full Text] [Related]
18. Fluconazole vs amphotericin B: "in vitro" comparative evaluation of the minimal inhibitory concentration (MIC) against yeasts isolated from AIDS patients.
Lombardi G; Gramegna G; Cavanna C; Michelone G
Microbiologica; 1990 Jul; 13(3):201-6. PubMed ID: 2273982
[TBL] [Abstract][Full Text] [Related]
19. [In vitro pharmacological study of fluconazole. Evaluation of an antifungal assay].
Duval F; Lavarde V
Pathol Biol (Paris); 1993 May; 41(5):469-73. PubMed ID: 8414680
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans.
Takahata S; Okutomi T; Ohtsuka K; Hoshiko S; Uchida K; Yamaguchi H
Med Mycol; 2005 May; 43(3):227-33. PubMed ID: 16010849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
